Use of a 2-dose schedule for human papillomavirus vaccination — updated recommendations of the Advisory Committee on Immunization Practices

Morbidity and Mortality Weekly Report

Volumn 65, Issue 49, 2016, Pages 1405-1408

  Meites, Elissa ^a   Kempe, Allison ^b,c   Markowitz, Lauri E ^a  

^a NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^b HPV Vaccines Work Group   (United States)

^c Children's Hospital Colorado   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ADULT; ADVISORY COMMITTEE; CHILD; FEMALE; HUMAN; IMMUNIZATION; MALE; PAPILLOMAVIRUS INFECTIONS; PUBLIC HEALTH SERVICE; STANDARDS; UNITED STATES; VACCINATION; YOUNG ADULT;

ADOLESCENT; ADULT; ADVISORY COMMITTEES; CENTERS FOR DISEASE CONTROL AND PREVENTION (U.S.); CHILD; FEMALE; HUMANS; IMMUNIZATION SCHEDULE; MALE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UNITED STATES; VACCINATION; YOUNG ADULT;

EID: 85007470614     PISSN: 01492195     EISSN: 1545861X     Source Type: Journal    
DOI: 10.15585/mmwr.mm6549a5     Document Type: Article

References (14)

1. Markowitz LE, Dunne EF, Saraiya M, et al. Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2014;63(No. RR-05).
2. Petrosky E, Bocchini JA Jr, Hariri S, et al. Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep 2015;64:300–4.
3. Viens LJ, Henley SJ, Watson M, et al. Human papillomavirus-associated cancers—United States, 2008–2012. MMWR Morb Mortal Wkly Rep 2016;65:661–6. http://dx.doi.org/10.15585/mmwr.mm6526a1
4. Iversen O-E, Miranda MJ, Ulied A, et al. Immunogenicity of the 9-valent HPV vaccine using 2-dose regimens in girls and boys vs a 3-dose regimen in women. JAMA 2016;316:2411–21. http://dx.doi.org/10.1001/jama.2016.17615
5. Food and Drug Administration. Prescribing information [package insert]. Gardasil 9 [human papillomavirus 9-valent vaccine, recombinant]. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2016. http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM426457.pdf
6. CDC. Grading of Recommendations Assessment, Development and Evaluation (GRADE) of a 2-dose schedule for human papillomavirus (HPV) vaccination. Atlanta, GA: US Department of Health and Human Services, CDC; 2016. https://www.cdc.gov/vaccines/acip/recs/grade/hpv-2-dose.html
7. Rubin LG, Levin MJ, Ljungman P, et al.; Infectious Diseases Society of America. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis 2014;58:e44–100. http://dx.doi.org/10.1093/cid/cit684
8. Ahmed F, Temte JL, Campos-Outcalt D, Schünemann HJ; ACIP Evidence Based Recommendations Work Group (EBRWG). Methods for developing evidence-based recommendations by the Advisory Committee on Immunization Practices (ACIP) of the U.S. Centers for Disease Control and Prevention (CDC). Vaccine 2011;29:9171–6. http://dx.doi.org/10.1016/j.vaccine.2011.08.005
9. Kreimer AR, Struyf F, Del Rosario-Raymundo MR, et al.; Costa Rica Vaccine Trial Study Group Authors; PATRICIA Study Group Authors; HPV PATRICIA Principal Investigators/Co-Principal Investigator Collaborators; GSK Vaccines Clinical Study Support Group. Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA Trials. Lancet Oncol 2015;16:775–86. http://dx.doi.org/10.1016/S1470-2045(15)00047-9
10. Kreimer AR, Rodriguez AC, Hildesheim A, et al.; CVT Vaccine Group. Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Natl Cancer Inst 2011;103:1444–51. http://dx.doi.org/10.1093/jnci/djr319
11. Sankaranarayanan R, Prabhu PR, Pawlita M, et al.; Indian HPV Vaccine Study Group. Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study. Lancet Oncol 2016;17:67–77. http://dx.doi.org/10.1016/S1470-2045(15)00414-3
12. Romanowski B, Schwarz TF, Ferguson L, et al. Sustained immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine administered as a two-dose schedule in adolescent girls: five-year clinical data and modeling predictions from a randomized study. Hum Vaccin Immunother 2016;12:20–9. http://dx.doi.org/10.1080/21645515.2015.1065363
13. Dobson SR, McNeil S, Dionne M, et al. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial. JAMA 2013;309:1793–802. http://dx.doi.org/10.1001/jama.2013.1625
14. Laprise JF, Markowitz LE, Chesson HW, Drolet M, Brisson M. Comparison of 2-dose and 3-dose 9-valent human papillomavirus vaccine schedules in the United States: a cost-effectiveness analysis. J Infect Dis 2016;214:685–8. http://dx.doi.org/10.1093/infdis/jiw227